Betulinic acid shows anticancer activity against equine melanoma cells and permeates isolated equine skin in vitro.

Summary

# Editorial Summary: Betulinic acid as a topical candidate for equine melanoma Equine malignant melanoma remains a significant clinical challenge in grey horses, with existing therapeutic options frequently proving inadequate or logistically difficult; this study investigated whether betulinic acid (BA), a naturally occurring triterpenoid compound, might offer promise as a topical treatment modality. Using in vitro models, researchers assessed BA's cytotoxic effects on primary equine melanoma cells and dermal fibroblasts, whilst simultaneously evaluating its capacity to permeate isolated equine skin—a critical prerequisite for any topical intervention. BA demonstrated selective anticancer activity against melanoma cells whilst showing minimal toxicity to normal dermal fibroblasts, and importantly, the compound successfully penetrated equine skin in measurable concentrations, suggesting adequate bioavailability for potential therapeutic effect. These findings indicate that topical BA warrants further investigation as a non-invasive option for managing cutaneous melanoma, particularly in cases where surgical excision or systemic therapies are contraindicated or declined. The work establishes a rational foundation for progressing to in vivo studies, though practitioners should recognise that in vitro efficacy does not guarantee clinical efficacy, and additional research into optimal formulation, dosing regimens, and safety profiles in living horses remains essential before clinical application.

Read the full abstract on PubMed

Key Findings

• •Betulinic acid demonstrated anticancer activity against primary equine melanoma cells in vitro
• •Betulinic acid permeates isolated equine skin, indicating potential for topical delivery
• •Study establishes in vitro proof-of-concept for BA as a potential topical therapy for equine melanoma

Conditions Studied

Tags